Contraindications
- Hypersensitivity to eperisone
Dosing: Adult
- Muscle tone improvement (neck-shoulder syndrome, low back pain) and spastic paralysis: 150 mg/day in 3 divided doses after meals; adjust for age and symptoms
Dosing: Altered kidney function
Eperisone is a centrally acting muscle relaxant with a short half-life (about 1.7 hours). The Japanese package insert contains no kidney-impairment guidance or kidney pharmacokinetic data; it advises dose reduction and caution in older adults. It has no US FDA label.
Kidney function measure: The Japanese package insert does not address kidney impairment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 150 mg/day in 3 divided doses after meals (50 mg three times daily), adjusted for age and symptoms (PMDA insert).
- CrCl 30–59 mL/min
- The Japanese package insert gives no kidney dosing or kidney pharmacokinetic data. Use with caution and specialist judgment.
- CrCl 15–29 mL/min
- The Japanese package insert gives no kidney dosing or kidney pharmacokinetic data. Use with caution and specialist judgment.
- CrCl <15 mL/min (not on dialysis)
- The Japanese package insert gives no kidney dosing or kidney pharmacokinetic data. Use with caution and specialist judgment.
- Hemodialysis (intermittent)
- Not studied in dialysis; no dose given.
- Peritoneal dialysis
- Not studied in dialysis; no dose given.
- CRRT
- Not studied in dialysis; no dose given.
- Dialyzable? Not stated.
- Monitoring Weakness, unsteadiness, drowsiness (reduce dose or stop; no driving). Shock, anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis: stop at once. Liver function (may worsen hepatic impairment) (PMDA insert). Proteinuria and raised BUN are listed adverse reactions; check urinalysis and kidney function if symptoms or in CKD.
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: PMDA (Japan) product information (April 2025). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- No pediatric trials (PMDA insert).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 50 mg
- Tablet: 50 mg
Registered products in the Philippines
18 products registered with the Food and Drug Administration (FDA) Philippines list Eperisone as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Eperisosne Hydrochloride (1 product). Products registered under these spellings are included in the table and marked.
All registered products18
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AltavanEperisone Hydrochloride | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Pharmakon Biotec Inc. | DRP-15759-05 | Sep 11, 2029 | |
EperibEperisone | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Baroque Pharmaceuticals Private LimitedIndia | AMB HK Enterprises Inc. | DRP-18746 | Sep 3, 2032 | |
EperiferEperisone Hydrochloride | 50 mg Film-Coated TabletAlu / Alu Blister pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Ferma Drug EnterprisesImporter: Pharmakon Biotec Inc. | DRP-15759-06 | Sep 11, 2029 | |
EperilifeEperisone hydrochloride | 50 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Flourish PharmaIndia | Biophil Medical Equipment and Supplies Trading | DRP-16988 | Sep 10, 2030 | |
Eperivin-50Eperisone Hydrochloride | 50 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India 174101 | Life And Health Source Pharmaceutical Distribution Co.Importer: Pharmakon Biotec Inc. | DRP-15759-07 | Sep 11, 2029 | |
EpertonEperisone hydrochloride | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc. | DRP-16043 | Oct 18, 2029 | |
EpizenEperisone hydrochloride | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Kodapharm Med Corp.Importer: Pharmakon Biotec Inc. | DRP-15759-04 | Sep 11, 2029 | |
EprelaxEperisone hydrochloride | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-15759-02 | Sep 11, 2029 | |
GoperisoneEperisone Hydrochloride | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Pharmakon Biotec Inc. | DRP-15759-03 | Sep 11, 2029 | |
KeersonEperisone hydrochloride | 50 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100’s) | Rx | Genom Biotech Pvt. Ltd.India | L’Keeran EnterprisesImporter: Nelpa Lifesciences Inc. | DRP-17754-01 | Mar 12, 2031 | |
Laxasaph-GE50Eperisone hydrochloride | 50 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences Inc. | DRP-17754 | Mar 12, 2031 | |
MyelaxEperisone Hydrochloride | 50 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Myungmoon Pharm. Co., Ltd.Republic of Korea | The Cathay Drug Co., Inc. | DR-XY43367 | Apr 28, 2029 | |
MyonalEperisone Hydrochloride | 50 mg TabletClear PVC/Aluminum Foil Blister Strip x 10's (Box of 100's) | Rx | Swiss Pharma Research Laboratories, Inc.Laguna | DKSH Market Expansion Services Philippines, Inc.Trader: Favorex Pte. Ltd. | DR-XY22030 | Oct 16, 2036 | |
50 mg Film-Coated TabletAlu/Alu blister pack x 10’s (Box of 100’s and 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | D'Conner PharmaImporter: Teramedix Pharma Trading Inc. | DRP-16043-02 | Oct 18, 2029 | ||
PerispaEperisone Hydrochloride | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Platinum Pharmaceuticals (Pvt.) Ltd.Pakistan | Wert Philippines, Inc. | DR-XY35442 | Feb 11, 2027 | |
ReduspasmEperisone hydrochloride | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc.. | DRP-15759 | Sep 11, 2029 | |
RetalaxEperisone Hydrochloride | 50 mg Film-Coated tabletAlu-Alu Blister Pack x 10's (Box of 100’s) | Rx | Magbro Healthcare Pvt. LtdIndia 174101 | Reta DrugImporter: Teramedix Pharma Trading Inc. | DRP-16043-01 | Oct 18, 2029 | |
SpasmirEperisone hydrochloride | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-15759-01 | Sep 11, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Methocarbamol | Adjust or monitor | Eye accommodation disorder reported with the related drug tolperisone. | Use with caution. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Weakness, unsteadiness, drowsiness
- Proteinuria, raised BUN (frequency not stated)
Serious
- Shock, anaphylaxis
- Toxic epidermal necrolysis, Stevens-Johnson syndrome
Monitoring parameters
- Weakness, unsteadiness, drowsiness (reduce dose or stop; no driving). Shock, anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis: stop at once. Liver function (may worsen hepatic impairment) (PMDA insert). Proteinuria and raised BUN are listed adverse reactions; check urinalysis and kidney function if symptoms or in CKD. Kidney
- Sedation and weakness; liver function in hepatic impairment
Pharmacokinetics
Key PK parameters
| Time to peak | 1.6 to 1.9 hours |
|---|---|
| Half-life | 1.6 to 1.8 hours |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Eperisone Hydrochloride 50 mg Tablet | ₱4.29–₱29.00Reference ₱11.50 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Eperisone hydrochloride |
| PNF listing | Oral: 50 mg tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Pharmaceuticals and Medical Devices Agency (Japan). Myonal tablets 50 mg / granules 10% package insert [PMDA (Japan) product information, April 2025; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987028511113
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Myonal tablets 50 mg and granules 10% (eperisone hydrochloride) [Japanese package insert, 2nd edition, revised April 2025; drug-information contact: Kaken Pharmaceutical Co., Ltd.]. (2025). Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987028511113
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .